Significantly expands IP to major cancer types in important US market
London, UK – 1st December 2020. Actimed Therapeutics, the clinical stage company focused on bringing innovation to the treatment of muscle wasting disorders, with a focus on cachexia, today announces that it has been granted US patent US 10,828,270 expanding its intellectual property rights directed to ACM-002 (S-oxprenolol) for the treatment of cancer cachexia.
The new patent contains claims which cover the treatment of the symptoms of cachexia in patients having a late stage cancer which is liver cancer, lung cancer, ovarian cancer, pancreatic cancer, melanoma, brain cancer, gastric cancer, oesophageal cancer, colorectal cancer, head and neck cancer, or haematological malignancy.
ACM-002 (S-oxprenolol) is the second in a new class of anabolic-catabolic transforming agents (ACTAs) under development by Actimed. Using a similar mode of action as Actimed’s lead asset, ACM-001 (S-pindolol), ACM-002 (S-oxprenolol) exhibits a multi-modal pharmacology designed to target the underlying pathophysiology of cachexia.
This new US patent is a continuation of Actimed’s US patent US 10,398,658 directed to the treatment of late stage liver cancer and extends patent coverage in the US to a wide range of major cancer types. This in turn strengthens Actimed’s global patent estate around ACM-002 (S-oxprenolol), which now includes broad coverage for the treatment of cancer cachexia for the US and all major European markets as well as a number of additional markets beyond this. All patents and applications in this family are owned by Actimed.
In addition, Actimed retains certain patent rights to ACM-002 (S-oxprenolol) in ALS (amyotrophic lateral sclerosis).
Robin Bhattacherjee, Actimed CEO, commented: “We are very pleased to enhance our US patent coverage for ACM-002 (S-oxprenolol) in cancer cachexia with the issue of this latest, broad patent which expands US protection to relevant cancer types out until 2034, consistent with our claims in Europe and other markets. There is no doubt that this adds significant value to ACM-002 (S-oxprenolol) given the commercial significance of the US market, and we will continue to further build our IP around this important molecule. Pre-clinical data has clearly shown the potential for ACM-002 (S-oxprenolol) to treat cancer cachexia, with the possibility of improving quality of life and extending survival for cancer patients. We look forward to communicating further on our future development plans”.